UBS AM
PCVX icon

UBS AM’s Vaxcyte PCVX Stock Holding History

UBS AM’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.6M Sell
371,550
-39,055
-10% -$2.12M ﹤0.01% 907
2026
Q1 		$23.9M Buy
410,605
+21,595
+6% +$1.17M 0.01% 821
2025
Q4 		$17.9M Sell
389,010
-9,134
-2% -$409K ﹤0.01% 884
2025
Q3 		$14.3M Sell
398,144
-156,864
-28% -$5.2M ﹤0.01% 952
2025
Q2 		$18M Buy
555,008
+41,010
+8% +$1.34M ﹤0.01% 1090
2025
Q1 		$19.4M Buy
513,998
+41,034
+9% +$3.28M 0.01% 981
2024
Q4 		$38.7M Buy
472,964
+64,690
+16% +$6.42M 0.01% 729
2024
Q3 		$46.7M Buy
408,274
+112,512
+38% +$10.1M 0.01% 686
2024
Q2 		$22.3M Buy
295,762
+187,750
+174% +$12.8M 0.01% 827
2024
Q1 		$7.38M Buy
108,012
+26,539
+33% +$1.84M ﹤0.01% 1107
2023
Q4 		$5.12M Buy
81,473
+6,975
+9% +$362K ﹤0.01% 1232
2023
Q3 		$3.8M Buy
74,498
+18,467
+33% +$911K ﹤0.01% 1331
2023
Q2 		$2.1M Hold
56,031
– – ﹤0.01% 1622
2023
Q1 		$2.1M Buy
56,031
+4,350
+8% +$185K ﹤0.01% 1622
2022
Q4 		$2.48M Buy
51,681
+17,053
+49% +$669K ﹤0.01% 1441
2022
Q3 		$831K Buy
34,628
+24,296
+235% +$616K ﹤0.01% 2077
2022
Q2 		$225K Buy
+10,332
New +$239K ﹤0.01% 2558

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

UBS AM's PCVX Position: Q2 2026 in Review

UBS AM reduced its Vaxcyte (PCVX) stake by 9.5% in Q2 2026, selling an estimated $2.12M and leaving 371,550 shares worth $21.6M. The position accounts for ﹤0.01% of the portfolio, ranked #907.

UBS AM first reported a position in PCVX in Q2 2022 and has held it in 17 quarters since. The position peaked at $46.7M in Q3 2024. 332 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • UBS AM held 371,550 shares of Vaxcyte worth $21.6M as of Q2 2026.
  • UBS AM sold 39,055 Vaxcyte shares in Q2 2026, an estimated $2.12M.
  • Vaxcyte made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #907 holding.
  • UBS AM first reported a position in Vaxcyte in Q2 2022 and has held it in 17 quarters since.
  • UBS AM's Vaxcyte position peaked at $46.7M in Q3 2024.
  • 332 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.